Dyslipidemia Signs and Symptoms

Signs and Symptoms

Definition

An abnormality in lipoprotein metabolism that results in elevations of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG), and/or non-high-density lipoprotein cholesterol (non-HDL-C) levels, or significantly reduced high-density lipoprotein cholesterol (HDL-C) levels
Increase in serum concentration of TC, LDL, TG or non-HDL-C is equivalent to increased risk for cardiovascular diseases

Etiology

Depends on the type of dyslipidemia
Hereditary disorders associated with primary dyslipidemia include familial hypercholesterolemia, familial hypertriglyceridemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia, chylomicronemia
Secondary causes include diabetes mellitus, diet, alcohol intake, hypothyroidism, renal failure, obstructive liver disease, Cushing’s syndrome, metabolic syndrome, medications (glucocorticoids, beta-blockers, thiazides, estrogen therapy)

Protecting adults against herpes zoster: Why it matters

25 Mar 2023

Herpes zoster occurs when the varicella zoster virus that lay dormant in the body after recovering from chickenpox reactivate later in life. Complications from herpes zoster can cause chronic, debilitating pain and disability. Three clinicians share why preventing herpes zoster matters for everyone.

Cardiorenal benefits of empagliflozin in elderly patients with T2DM, HF or CKD

Prof. Silvio Inzucchi, Prof. Michael Böhm, 18 Oct 2023

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated cardiorenal benefits in patients with type 2 diabetes mellitus (T2DM) and those with heart failure (HF) or chronic kidney disease (CKD) with or without diabetes. However, misconceptions may lead to inertia in treatment initiation in elderly patients. At a Boehringer Ingelheim–sponsored symposium organized by the Hong Kong Geriatrics Society, Professor Silvio Inzucchi of Yale School of Medicine, New Haven, Connecticut, US, and Professor Michael Böhm of Saarland University, Saarbrücken, Saarland, Germany, presented pivotal trial and real-world data demonstrating empagliflozin’s cardiorenal benefits and safety in elderly patients with these closely interrelated cardio-renalmetabolic (CRM) conditions.

Using time in range to optimize insulin therapy in patients with T2DM

Dr. Tin-Wai Wong, 12 Jun 2023

Time spent within target blood glucose range (ie, time in range [TIR]) evaluated through continuous glucose monitoring (CGM) has emerged as an important complementary metric for assessing day-to-day glycaemic control in diabetic patients. In an interview with MIMS Doctor, Dr Tin-Wai Wong, Specialist in Endocrinology, Diabetes & Metabolism at the Ruttonjee Hospital in Hong Kong, discussed the importance of TIR as an adjunct to other glycaemic parameters and shared case studies on how TIR may help fine-tune insulin therapy in patients with type 2 diabetes mellitus (T2DM).